1. Squamous cell cancer of the temporal bone: a review of the literature
- Author
-
Shakeel R. Saeed, Matt Lechner, Liam Sutton, Liam Masterson, Charlotte Murkin, Michael J Wareing, Taranjit Tatla, and Paul O'Flynn
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Otology ,Disease ,Malignancy ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Temporal bone ,medicine ,Humans ,Stage (cooking) ,030223 otorhinolaryngology ,Neoplasm Staging ,Retrospective Studies ,Squamous cell cancer ,business.industry ,Temporal Bone ,General Medicine ,Prognosis ,medicine.disease ,Survival Rate ,Radiation therapy ,Otorhinolaryngology ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Neurosurgery ,business - Abstract
Background and aims Squamous cell carcinoma (SCC) of the temporal bone is a rare malignancy accounting for only 0.2% of head and neck cancers. There is currently no clear consensus on staging or common approach to management. It is the aim of this work to provide the readers with a review of the current literature on this malignancy. Methods A literature review was performed identifying 16 case series with patient numbers ranging from 12 to 124. A total of 708 patients were included in this review, 67% presented with advanced disease. 578 cases were managed operatively with lateral temporal bone resection, some underwent local resection alone in early stage disease. In all studies radiation therapy was used as an adjunct to some degree. Results More than half of studies reported 100% either 2-, 3- or 5-year survival for T1 and T2 disease with no nodal involvement. Survival correlated with disease stage and in five studies SCC differentiation was found to be a significant prognostic factor. Post-operative radiotherapy was found to improve survival in only one study. Conclusions Temporal bone SCC is a readily treatable malignancy in early stage disease, however late stage disease has a poor prognosis. Differentiation of the SCC and stage of disease at presentation appear to have the greatest influence on 5-year survival rates. Further work is required in both the identification of early stage disease and in the treatment of later T3 and T4 lesions.
- Published
- 2020
- Full Text
- View/download PDF